Insights

Gathering insights about Apli…

Similar companies to Apli

Apli Tech Stack

Apli uses 8 technology products and services including Google Ads, Facebook Pixel, Amazon Web Services, and more. Explore Apli's tech stack below.

Google Ads
Advertising
Facebook Pixel
Analytics
Amazon Web Services
Cloud Hosting
Webflow
Page Builders
Cloudflare Bot Management
Security
Correos
Transportation And Fleet Management
HTTP/3
Web & Portal Technology
Google Analytics
Web Analytics

Media & News

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private transaction extended to March 31, 2025
Mar 18, 2025 | www.globenewswire.com
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission Further strengthened government partnerships, reinforcing Appili's position as a key player in biodefense and infectious disease solutions. HALIFAX, Nova Scotia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2025, which ended on December 31, 2024.
Feb 14, 2025 | www.globenewswire.com
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce receipt of the final order of the Ontario Superior Court of Justice (Commercial List) for the plan of arrangement (the “Arrangement”) pursuant to which Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc., will acquire all of the issued and outstanding Class A common shares of the Company (the “Transaction”). As previously announced, the Transaction was overwhelmingly approved by the Company's shareholders at a special meeting held on November 6, 2024.
Nov 19, 2024 | www.globenewswire.com
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission HALIFAX, Nova Scotia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2025, which ended on September 30, 2024. All figures are stated in Canadian dollars unless otherwise stated.
Nov 14, 2024 | www.globenewswire.com
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire all issued and outstanding Class A common shares of Appili. For additional information a.
Nov 07, 2024 | www.businesswire.com
Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its special meeting of shareholders held earlier today (the “Meeting”). Shareholders of the Company (the “Shareholders”), overwhelmingly voted in favour of a special resolution approving a plan of arrangement pursuant to which Aditxt Inc. (NASDAQ:ADTX) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc. will acquire all of the issued and outstanding Class A common shares of the Company (the “Appili Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).
Nov 06, 2024 | www.globenewswire.com
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801, and agreed on the necessary registration package to support a New Drug Application (“NDA”). ATI-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.
Oct 31, 2024 | www.globenewswire.com

Apli's Email Address Formats

Apli uses at least 1 format(s):

Apli Email Formats	Example	Percentage
First@apli.jobs	John@apli.jobs	48%
First.Last@apli.jobs	John.Doe@apli.jobs	35%
F.Last@apli.jobs	J.Doe@apli.jobs	13%
Middle@apli.jobs	Michael@apli.jobs	4%

Frequently Asked Questions

Where is Apli's headquarters located?

Apli's main headquarters is located at Campeche 233 Cuauhtémoc, Ciudad de México, Ciudad de Mexico 06140 MX. The company has employees across 6 continents, including North AmericaAsiaSouth America.

What is Apli's stock symbol?

Apli is a publicly traded company; the company's stock symbol is APLIF.

What is Apli's official website and social media links?

Apli's official website is apli.jobs and has social profiles on LinkedIn.

How much revenue does Apli generate?

As of January 2025, Apli's annual revenue reached $15M.

What is Apli's NAICS code?

Apli's NAICS code is 5112 - Software Publishers.

How many employees does Apli have currently?

As of January 2025, Apli has approximately 117 employees across 6 continents, including North AmericaAsiaSouth America. Key team members include Chief Of Staff: N. P. R.Chief Of Staff: R. G.Head Of Sales: M. C.. Explore Apli's employee directory with LeadIQ.

What industry does Apli belong to?

Apli operates in the Software Development industry.

What technology does Apli use?

Apli's tech stack includes Google AdsFacebook PixelAmazon Web ServicesWebflowCloudflare Bot ManagementCorreosHTTP/3Google Analytics.

What is Apli's email format?

Apli's email format typically follows the pattern of . Find more Apli email formats with LeadIQ.

How much funding has Apli raised to date?

As of January 2025, Apli has raised $1M in funding. The last funding round occurred on May 02, 2019 for $1M.

When was Apli founded?

Apli was founded in 2016.

Apli

Software DevelopmentCiudad de Mexico, Mexico51-200 Employees

Apli is a recruiting automation platform that connects candidates to jobs 50 times faster than with traditional methods. With technology, we can fill billions of work days that are currently being lost because companies can’t hire fast enough or bad candidate profiling leads to high turnover. Apli was named in 2019 and 2018 to Fast Company's list of Top 10 Most Innovative Companies In Latin America and was recognized as a leader in Future of Work solutions by MIT’s Initiative on the Digital Economy.

Company Overview

Headquarters: Campeche 233 Cuauhtémoc, Ciudad de México, Ciudad de Mexico 06140 MX
Website: apli.jobs
Stock Symbol: APLIF
NAICS Code: 5112 - Software Publishers
Founded: 2016
Employees: 51-200

Media & News

Funding & Financials

$1M
Apli has raised a total of $1M of funding over 3 rounds. Their latest funding round was raised on May 02, 2019 in the amount of $1M.
$10M$50M
Apli's revenue is in the range of $10M$50M

Funding & Financials

$1M
Apli has raised a total of $1M of funding over 3 rounds. Their latest funding round was raised on May 02, 2019 in the amount of $1M.
$10M$50M
Apli's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Apli

LiveCareer

Monster

Resumonk

Indeed

Glassdoor

CV-Library

LinkedIn

ZipRecruiter

CareerBuilder

Apli Tech Stack

Media & News

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Apli's Email Address Formats

Frequently Asked Questions

Where is Apli's headquarters located?

What is Apli's stock symbol?

What is Apli's official website and social media links?

How much revenue does Apli generate?

What is Apli's NAICS code?

How many employees does Apli have currently?

What industry does Apli belong to?

What technology does Apli use?

What is Apli's email format?

How much funding has Apli raised to date?

When was Apli founded?

Apli

Company Overview

Media & News

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?